

Product Information

Product ID R1217

CAS No. 923032-37-5

Chemical Name Refametinib

Synonym Refametinib, BAY 869766; N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide; BAY 869766; BAY 8697661

Formula C₁₉H₂₀F₃IN₂O₅S

Formula Wt. 572.34

Melting Point


Purity ≥98%

Solubility DMSO 100 mg/mL (174.72 mM)
Ethanol 100 mg/mL (174.72 mM)
Water Insoluble

Store Temp -20°C

Ship Temp Ambient

Description RDEA119 inhibits MEK1/2 and exhibits anticancer chemotherapeutic activity. RDEA119 is currently in clinical trials as a potential treatment for a variety of advanced cancers. This compound inhibits proliferation in thyroid cancer cells, including those containing V600E B-Raf mutations. RDEA119 also inhibits tumor growth in animal models of melanoma, colon cancer, and epidermal carcinoma.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
R1217	1 mg	\$98.50
R1217	5 mg	\$197.20
R1217	10 mg	\$318.50

References Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.